https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53996 Wed 28 Feb 2024 16:39:56 AEDT ]]> The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52963 Wed 28 Feb 2024 16:09:43 AEDT ]]> The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54997 Wed 27 Mar 2024 16:38:22 AEDT ]]> A legacy of hope https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55001 Wed 27 Mar 2024 16:38:06 AEDT ]]> Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45109 n = 230 patients (mean age 65, males n = 124 (53.9%)) were treated with bevacizumab during the study period. N = 28 patients were admitted to hospital for a major cardiovascular-related event. Higher total treatment dose (p < 0.05), concomitant hypertension (p = 0.005), diabetes (p = 0.04), atrial fibrillation (p = 0.03), and lack of use of statin therapy (p = 0.03) were key contributors to hospital admission. Conclusions: Results of our study highlight the fact that patients with concomitant baseline cardiovascular disease/risk factors are at an increased risk of cardiovascular hospitalization related to bevacizumab treatment. Careful baseline cardiovascular assessment may be an essential step to minimize cardiovascular complications.]]> Wed 26 Oct 2022 13:22:56 AEDT ]]> Postmortem brain donations vs premortem surgical resections for glioblastoma research: viewing the matter as a whole https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47116 Wed 14 Dec 2022 12:11:17 AEDT ]]> A qualitative study investigating Australian cancer service outpatients’ experience of distress screening and management: what is the personal relevance, acceptability and improvement opportunities from patient perspectives? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47065 Tue 30 Apr 2024 09:57:14 AEST ]]> Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51990 Tue 26 Sep 2023 10:53:57 AEST ]]> Understanding the value of brain donation for research to donors, next-of-kin and clinicians: A systematic review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54249 Tue 13 Feb 2024 13:26:06 AEDT ]]> Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45363 Thu 27 Oct 2022 11:46:23 AEDT ]]> Adult medulloblastoma in an Australian population https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51870 Thu 21 Sep 2023 10:24:07 AEST ]]> Utility of selection methods for specialist medical training: a BEME (best evidence medical education) systematic review: BEME guide no. 45 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36286 Thu 19 Mar 2020 17:51:51 AEDT ]]> ProNGF Expression and Targeting in Glioblastoma Multiforme https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50637 Mon 31 Jul 2023 16:21:11 AEST ]]> Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51948 Fri 22 Sep 2023 17:06:07 AEST ]]> Results of a survey of cancer patients' willingness to travel to participate in a clinical trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46154 Fri 11 Nov 2022 19:05:54 AEDT ]]>